Skip to main content

Table 5 Risk factors potentially associated with VAP

From: Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy

 

VAP

No VAP

P value

 

Number (%) or mean ± SD

Number (%) or mean ± SD

 

Age (years)

60 ± 14

57 ± 16

0.71

Male sex

79 (81)

159 (66)

0.006

Glasgow Coma Scale score on admission

10.9 ± 4.9

11.8 ± 4.2

0.09

SAPS II on inclusion

49 ± 15

49 ± 15

0.47

PaO2:FIO2 on inclusion

106 ± 33

111 ± 40

0.48

Respiratory system compliance on inclusion (ml/cm of water)

30 ± 10

32 ± 11

0.72

Received NMBA during the first 48 hours

48 (49)

129 (54)

0.36

Stress-ulcer prophylaxisa

81 (87)

206 (88)

0.80

Enteral nutritiona

80 (86)

179 (77)

0.09

Emergency reintubationa

18 (19)

28 (12)

0.11

Tracheostomya

30 (32)

53 (23)

0.15

Transport out of the ICUa

42 (45)

66 (28)

0.009

Subglottic secretion drainagea

11 (11)

44 (18)

0.14

Selective digestive decontaminationa

8 (9)

18 (8)

0.82

Corticosteroids for ARDSa

22 (22)

43 (18)

0.33

Vasopressora

91 (93)

215 (89)

0.31

Renal replacement therapy

37 (38)

81 (34)

0.47

Prone positiona

21 (21)

64 (27)

0.46

  1. aPrior VAP (VAP group) or duration of mechanical ventilation + 2 days for the no-VAP group; NMBA, neuromuscular blocking agents; SAPS II, Simplified Acute Physiology Score II; VAP, ventilator-associated pneumonia.